IVIRMA’s scientific innovation continues to revolutionize the industry

Our history

IVI was founded in 1990 by Professors José Remohí and Antonio Pellicer, and became a leader in fertility treatment in Europe and Latin America.

Its success rates have been one of the best in the sector since its inception, thanks to its continuous efforts in the teaching and research fields, which have put this company on the international vanguard of fertility care.

​​​​​​​RMA was founded in 1999 by Drs. Paul Bergh, Richard Scott and Michael Drews, quickly becoming a leader in reproductive medicine in the United States.

​​​​​​​Its success rates were consistently higher than the national average, thanks to cutting-edge research and state-of-the-art technology, and the group was soon recognized as a leader in the Americas.

​​​​​​​​​​​​​​IVI and RMA merged in 2017, a turning point that transformed the assisted reproduction industry, creating the only global company in Europe, the United States and Latin America. The company is expected to finish 2019 with 65 clinics and more than 67,000 assisted reproduction treatments.

​​​​​​​IVI and RMA both place great importance on research, high-quality scientific results, and a common culture with a single objective: to achieve the best results for patients.

MOST RELEVANT MILESTONES

1990 - 1999

1994

ICSI with testicular biopsy

1995

Pregnancy from frozen testicular sperm

1996

Cytoplasmic transfer for poor oocyte quality

2005

Clinical metabolomic assessment of spent culture media to predict delivery

2007

Cryotop oocyte vitrification study

2008

Rapid 24 chromosome PGT-A pregnancy

2010

Baby born after using Embryoscope data for embryo selection

2000 - 2010

2011 - 2014

2013

Trial showing that single embryo transfer with PGT-A attains equivalent pregnancy rates to multiple embryo transfers

2013

Trial evaluating the safety of embryo biopsy

2013

Prospective assessment of the predictive value of PGT-A results non-selection study

2014

Study shows birthweight of IVF singletons are approximately equal to national percentiles

2016

Trial using NexGen sequencing-based PGT-A

2018

Trial evaluating autologous mitochondrial transfer to oocytes

2018

Three pregnancies from ovarian rejuvenation / activation

2019

NexGen PGT-A non-selection study: Demonstrates extreme high predictive value of aneuploidy screening results, and is only validated assay in the world

2019

Prospective study demonstrating stimulated IVF as safe as natural cycle IVF

 

2015 - Present